OncoMatch/Clinical Trials/NCT06522828
A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients
Is NCT06522828 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including SSGJ-707 and carboplatin for advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer.
Treatment: SSGJ-707 · carboplatin · paclitaxel — This is an open, multicenter Phase II clinical study of SSGJ-707 combined with chemotherapy in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer. The objective is to evaluate the safety, tolerability and antitumor activity of SSGJ-707 in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Ovarian Cancer
Endometrial Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06522828 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify